Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp
(NQ:
LEXX
)
3.650
-0.260 (-6.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
238,554
Open
3.890
Bid (Size)
3.600 (1)
Ask (Size)
3.960 (1)
Prev. Close
3.910
Today's Range
3.540 - 4.120
52wk Range
0.8442 - 6.850
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting
September 03, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
September 03, 2024
Via
ACCESSWIRE
Performance
YTD
+182.95%
+182.95%
1 Month
+7.67%
+7.67%
3 Month
-8.75%
-8.75%
6 Month
+7.99%
+7.99%
1 Year
+284.21%
+284.21%
More News
Read More
12 Health Care Stocks Moving In Monday's Intraday Session
September 02, 2024
Via
Benzinga
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results
August 29, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
First Results from Lexaria's Second GLP-1 Human Pilot Study
August 27, 2024
Via
ACCESSWIRE
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
August 22, 2024
Via
ACCESSWIRE
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
August 21, 2024
Via
ACCESSWIRE
Positive Results from Lexaria's Molecular Characterization Study
August 19, 2024
Via
ACCESSWIRE
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
August 29, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
August 27, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
August 27, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market
August 26, 2024
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
August 22, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
August 22, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control
August 21, 2024
Via
Investor Brand Network
Topics
Animal Testing
Intellectual Property
Exposures
Animal Testing
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
August 19, 2024
Via
Investor Brand Network
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
August 19, 2024
Via
CannabisNewsWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule
August 16, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment
August 16, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Financial Results; Offers a Roadmap for its Key GLP-1 Study Program
August 12, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
August 08, 2024
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
August 08, 2024
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Recent Animal Study
August 06, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study
July 31, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
July 22, 2024
Via
CannabisNewsWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.